secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0000950170-23-042474
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health Q2 revenue down 70% to $161K, net loss improves, approves reverse split
--------------------------------------------------------------------------------

- Q2 revenue $161K (down 70% YoY); net loss $2.1M (from $3.0M).
- Gross margin rose to 37.5% on price increases and cost cuts.
- Cash $2.7M at June 30; raised $4.8M net via stock sales July–Aug.
- Stockholders approved reverse stock split (1:5 to 1:100) to meet Nasdaq minimum bid.
- Signed Cardinal Health distribution deal; started Feinstein pilot for vagus nerve therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017023042474/0000950170-23-042474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017023042474/tivc-20230811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-042474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer